Form 4: Surmodics Executive Sells Shares Post-Merger

Joseph J. Stich, SVP of HR and President IVD at Surmodics Inc., reported the disposition of all common stock and derivative securities following the company's merger with BCE Parent, LLC.

Summary

• Surmodics Inc. completed a merger with BCE Parent, LLC, where Surmodics became a wholly-owned subsidiary.
• Each share of Surmodics common stock was automatically cancelled and converted into the right to receive $43.00 per share in cash.
• Joseph J. Stich, an executive, disposed of 61,631 shares of common stock as a result of the merger.
• All outstanding restricted stock units (RSUs) held by Mr. Stich vested immediately prior to the merger and were converted to cash at $43.00 per share.
• Unexercised employee stock options were cancelled and converted into a cash payment equal to the product of the number of shares subject to the option multiplied by the excess, if any, of the $43.00 merger consideration over the option's exercise price.
• Mr. Stich no longer beneficially owns, directly or indirectly, any shares of Surmodics common stock.

Sentiment

Score: 7

Explanation: The filing reports the definitive completion of a merger, providing a clear cash exit for shareholders and equity award holders. This is a conclusive event, generally positive for those realizing value, but marks the end of the company's public trading.

Positives

• Completion of the merger provides liquidity to former public shareholders at $43.00 per share.
• Reporting person received cash for vested RSUs and in-the-money stock options, realizing value from their equity awards.

Negatives

• Surmodics Inc. is no longer a publicly traded company, removing it from public investment portfolios.
• Stock options with an exercise price higher than the $43.00 merger consideration resulted in no cash payout for the reporting person.

Future Outlook

The filing reports a completed merger, resulting in Surmodics Inc. becoming a wholly-owned private subsidiary. As such, there is no forward-looking guidance provided for the former publicly traded entity.

Industry Context

This merger signifies a consolidation event within the medical device and in vitro diagnostics (IVD) industry, where Surmodics operates. Such acquisitions are common strategies for larger entities to expand market share, acquire specialized technology, or integrate intellectual property, reflecting ongoing M&A activity in the sector.

Comparison to Industry Standards

• The $43.00 per share cash consideration represents the final valuation for Surmodics, Inc. in this specific acquisition, which would typically be assessed against industry valuation multiples (e.g., EV/EBITDA, P/S) for comparable companies at the time of the merger agreement.
• The conversion of common stock, restricted stock units, and in-the-money stock options into cash is a standard and expected mechanism for liquidity events in all-cash mergers across industries.

Stakeholder Impact

• Shareholders: Received $43.00 per share in cash, concluding their investment in the publicly traded company.
• Employees (including the reporting person): Equity awards were converted to cash, providing a liquidity event. The reporting person's role continues within the new private ownership structure.

Key Dates

Recommendation

Surmodics Inc. has been acquired by BCE Parent, LLC, and is now a private entity. Public shareholders received $43.00 per share in cash, and the stock is no longer traded on public exchanges. Any remaining shares would be automatically converted, making a 'sell' recommendation the only logical action for investors to realize the cash value if they had not already.

Keywords

Surmodics, SRDX, Merger, Form 4, Insider Transaction, Stock Options, RSU, Beneficial Ownership, Joseph J. Stich, BCE Parent, LLC, Cash Out